OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
M&A Transactions
M&A Transaction Chart
Viridian publishes weekly data on M&A transactions in the Cannabis/CBD/Psychedelic industries. This data includes information about the buyer and seller (public/private, state/country location), deal size, deal structure (cash, stock, earn-out), pricing, share information, and deal implied valuation.
Week ended 01/27/2023
Week ended 01/27/2023
This Section is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
M&A Transactions Commentary
Week ended 01/27/2023
The Largest Closed M&A Deal of the Week:
- On January 24, 2023, 22nd Century Group inc. (XXII: Nasdaq), a leading competitor in the reduced nicotine tobacco, hemp/cannabis, and advanced plant technology sectors, announced the acquisition of privately held Pharmatech Ltd., a leading UK distributor of cannabinoids.
- The total upfront consideration of $.65M was paid in cash. An additional three-year earnout provision is tied to revenue milestones.
- Pharmatech’s products include CBD isolate and finished products like gummies, oils, and tinctures.
- XXII intends to utilize its newly opened distribution facility in the Netherlands and the Pharmatech acquisition to scale its operations in the European consumer products sector.
Week ended 01/27/2023
This is the MA basic
Additional content is available to Premium and Enterprise users. Please purchase a higher tier membership to see more.
Viridian publishes weekly insights on the M&A landscape in the Cannabis/CBD/Psychedelic industries. These insights typically highlight the most interesting/meaningful M&A transactions for that week, and commentary on market conditions, M&A deal structures, target regions for acquirers, and industry sectors ripe for consolidation.